Partners from the International Decision Support Initiative (iDSI) join the 2nd China Health Technology Assessment Conference organised by the China National Health Development Research Center (CNHDRC) on 26-27 October 2019 in Beijing, China. The event brings together China’s high-level representati

HITAP was requested to provide support to the Beijing Children\'s Hospital and the China National Health Development Research Center in their efforts to develop a system for evaluating pediatric drugs in China.63374054HM039F0China,Pediatrics Guideline

The past few years have seen significant progress in the development of Health Technology Assessment (HTA) in China. The China National Health Development Research Center (CNHDRC), the national focal point for HTA in China, has stepped up efforts to roll out HTA activities in many ways in order to s

(Reuters) – Chinese police have detained almost 2,000 people in a nationwide sweep on fake drugs, seizing more than $180 million worth of counterfeit products and destroying some 1,100 production facilities, the public security ministry said on Sunday.The operation, involving around 18,000 police of

Chayapat Rachatan is currently a Project Associate at HITAP. She supports the HTA and health system research. Her research studies focus on COVID-19 policy research and decision support, effectiveness evaluation of COVID-19 vaccine chatbot, cost analysis of governance system in health sector, situational analysis of infectious disease modelling in

Abstract A trend towards charging for access to research findings, tools and databases is becoming more prominent globally. But charging for the use of research tools and databases that are vital to research supporting national and international policy development might be unjustified. Financial

Summary The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 20

Cetuximab is provided for mCRC patients with positive KRAS wild type, and also head and neck cancer patients as indicated in the Indonesian National Drug Formulary. However, currently, it is also used for indications not specified in the National Drug Formulary. Adding cetuximab to chemothera

A new way to screen poor women for cervical cancer was introduced this month in El Salvador, using a test that was originally developed in China.Cervical cancer was once the leading cancer killer of women in the United States, but deaths have been dramatically reduced in the last 50 years as a resul

“Health donors, policymakers, and practitioners continuously make life-and-death decisions about which type of patients receive what interventions, when, and at what cost. These decisions—as consequential as they are— often result from ad hoc, nontransparent processes driven more by inertia